Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Tricida, Inc.    TCDA

TRICIDA, INC.

(TCDA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/20/2020 02/21/2020 02/24/2020 02/25/2020 02/26/2020 Date
36.33(c) 36.93(c) 35.12(c) 33.71(c) 32.76(c) Last
165 911 131 565 178 448 238 806 398 210 Volume
+1.25% +1.65% -4.90% -4.01% -2.82% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -180 M
Net income 2019 -178 M
Finance 2019 236 M
Yield 2019 -
Sales 2020 14,2 M
EBIT 2020 -231 M
Net income 2020 -238 M
Finance 2020 22,8 M
Yield 2020 -
P/E ratio 2019 -8,79x
P/E ratio 2020 -7,03x
EV / Sales2019 -
EV / Sales2020 113x
Capitalization 1 625 M
More Financials
Company
Tricida, Inc. is a late-stage pharmaceutical company focused on the discovery and clinical development of non-absorbed therapeutics to address renal, metabolic and cardiovascular disease. The Company's lead program, TRC101 is a treatment for chronic kidney disease (CKD). The Company is engaged in... 
Sector
Biotechnology & Medical Research
Calendar
02/27 | 04:30pmEarnings Call
More about the company
Surperformance© ratings of Tricida, Inc.
Trading Rating : Investor Rating : -
More Ratings
Latest news on TRICIDA, INC.
02/24TRICIDA : to Present at the Cowen 40th Annual Health Care Conference
BU
02/19TRICIDA : to Report Fourth Quarter and Year End 2019 Financial Results and Host ..
BU
02/07TRICIDA : A statement of beneficial ownership of common stock by certain persons
PU
01/13TRICIDA, INC. : Regulation FD Disclosure (form 8-K)
AQ
01/07TRICIDA : to Present at the 38th Annual J. P. Morgan Healthcare Conference
BU
2019TRICIDA : Announces Hiring of Elizabeth Faust, Ph.D., as Senior Vice President o..
BU
2019TRICIDA : to Present at the Evercore Annual Global Healthcare Conference
BU
2019TRICIDA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
2019TRICIDA, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2019TRICIDA : Announces Third Quarter 2019 Financial Results
BU
2019TRICIDA : Announces FDA Acceptance of New Drug Application for Veverimer
BU
2019TRICIDA : to Report Third Quarter Financial Results and Host Conference Call and..
BU
2019TRICIDA : to Host Investor Day on October 15, 2019
BU
2019TRICIDA : Announces Multiple Data Presentations on Metabolic Acidosis to be Give..
BU
2019TRICIDA : Launches Metabolic Acidosis Insights, an Online Educational Resource f..
BU
More news
News in other languages on TRICIDA, INC.

- No features available -

More news
Sector news : Biotechnology & Medical Research - NEC
02/26GILEAD SCIENCES : to Kick Off Its Own Studies of Potential Coronavirus Drug--Upd..
DJ
02/26GILEAD SCIENCES : to Kick Off Its Own Studies of Potential Coronavirus Drug
DJ
02/26Google Cloud Signs Deal With SADA Systems in Enterprise Push -- Update
DJ
02/26Google Cloud Signs Deal With SADA Systems in Enterprise Push
DJ
02/26NEW CHINESE BILLIONAIRES OUTPACE U.S : Hurun
RE
More sector news : Biotechnology & Medical Research - NEC
Chart TRICIDA, INC.
Duration : Period :
Tricida, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRICIDA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 47,50  $
Last Close Price 32,76  $
Spread / Highest target 52,6%
Spread / Average Target 45,0%
Spread / Lowest Target 28,2%
EPS Revisions
Managers
NameTitle
Gerrit Klaerner President, Chief Executive Officer & Director
Klaus R. Veitinger Chairman
Geoffrey M. Parker Chief Financial Officer & Senior Vice President
Wilhelm Stahl Chief Technology Officer & Senior Vice President
Elizabeth A. Faust Senior Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
TRICIDA, INC.-13.20%1 625
LONZA GROUP16.73%31 368
IQVIA HOLDINGS INC.-3.31%28 934
SEATTLE GENETICS, INC.-1.88%19 359
CELLTRION, INC.-2.03%18 959
INCYTE CORPORATION-11.45%16 761